Ms. Broadfoot currently serves as the Chief Financial Officer of aTyr Pharma, Inc., a position she has held since July 2018. From January 2017 to July 2018, she served as Chief Financial Officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations for the US-based pharmaceutical and bioceutical entities, as well as the establishment of operations, corporate governance, finance and accounting, and investor relations functions, among other responsibilities.
Prior to Emerald Health, Ms. Broadfoot served as Vice President, US Corporate Controller, at GW Pharmaceuticals from May 2016 to January 2017. While at GW Pharmaceuticals, her responsibilities included establishing US commercial operations and implementing US public company financial and accounting standards in connection with the transfer of corporate operations from the UK to the US. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as Chief Financial Officer of Vical Inc. from October 2004 to March 2013, where she had oversight of finance, investor relations, manufacturing, information technology, human resources, and business development.
Ms. Broadfoot holds a Bachelor of Science degree in business administration and accounting from San Diego State University and is a certified public accountant.